Sun Shujun, Li Jie, Qin Dingmei, Yang Xiaoxiao, Zhang Huilin, Yang Yue, Li Mengmeng, Jin Ruihua, Dai Jianye, Liu Yong
School of Biology and Food Engineering, Fuyang Normal University, Fuyang, China.
Anhui Rural Revitalization Collaborative Technology Service Center, Fuyang Normal University, Fuyang, China.
Front Pharmacol. 2025 Jul 11;16:1614167. doi: 10.3389/fphar.2025.1614167. eCollection 2025.
Preeclampsia stands as a leading cause of maternal mortality. Scutellariae Radix and Atractylodis Macrocephalae Rhizoma (SA) is a commonly employed traditional Chinese medicine pair in the treatment of preeclampsia, yet the underlying mechanisms of their protective effects against preeclampsia remain elusive.
In this study, the N- nitro-L-arginine methyl ester (L-NAME) was utilized to establish a preeclamptic pregnant mouse model, and the protective effects of SA were systematically evaluated. A comprehensive approach integrating network pharmacology analysis, quantitative proteomics, and in vitro experiments was adopted to probe into the relevant mechanisms.
It was demonstrated that SA could significantly ameliorate the systolic blood pressure, urinary protein levels, and pathological damage in the kidneys and placenta of mice. Moreover, in vitro experiments further validated the promoting effects of SA, baicalin, and atractylenolide I on the proliferation and migration of HTR-8/SVneo cells. Baicalin and atractylenolide I are the main active and quality control components of SA. Network pharmacology analysis, quantitative proteomics and molecular docking revealed that the PI3K/Akt pathway is a potential mechanism through which SA alleviates preeclampsia. Further investigations showed that SA could reverse L-NAME-induced inhibition of the PI3K/p-Akt/Akt signaling pathway, upregulating eNOS expression and ultimately alleviating vasoconstriction and other preeclampsia-related symptoms.
SA has the capacity to improve preeclampsia-induced increases in blood pressure and urinary protein, holding promise as a novel strategy for the treatment of preeclampsia.
子痫前期是孕产妇死亡的主要原因。黄芩和白术(SA)是治疗子痫前期常用的中药药对,但其对子痫前期保护作用的潜在机制仍不清楚。
在本研究中,利用N-硝基-L-精氨酸甲酯(L-NAME)建立子痫前期妊娠小鼠模型,并系统评估SA的保护作用。采用网络药理学分析、定量蛋白质组学和体外实验相结合的综合方法探讨相关机制。
结果表明,SA可显著改善小鼠的收缩压、尿蛋白水平以及肾脏和胎盘的病理损伤。此外,体外实验进一步验证了SA、黄芩苷和白术内酯I对HTR-8/SVneo细胞增殖和迁移的促进作用。黄芩苷和白术内酯I是SA的主要活性成分和质量控制成分。网络药理学分析、定量蛋白质组学和分子对接显示,PI3K/Akt信号通路是SA缓解子痫前期的潜在机制。进一步研究表明,SA可逆转L-NAME诱导的PI3K/p-Akt/Akt信号通路抑制,上调eNOS表达,最终缓解血管收缩和其他子痫前期相关症状。
SA有能力改善子痫前期引起的血压升高和尿蛋白增加,有望成为治疗子痫前期的新策略。